ClinicalTrials.gg
CompletedNCT06053853Updated Nov 18, 2023

Post Marketing Surveillance of Diphtheria Antitoxin (DAT)

A Phase 4 interventional study of Diphtheria Antitoxin in Safety Issues, sponsored by PT Bio Farma. Completed at 1 site in Indonesia. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by PT Bio Farma · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jan 2023, registered Sep 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
1 Year to 70 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the safety profile of Diphtheria Antitoxin

Read the detailed description

To assess the occurrence of serum sickness after Diphtheria Antitoxin administration.

To assess local and systemic reactions within 24 hours to 10 days. To assess the occurrence of positive reactions after the sensitivity test (skin test). To assess the presence of SAE after Diphtheria Antitoxin administration.

02

Conditions studied

  • Safety Issues
03

In context

Lead sponsor

PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a probable diagnosis or laboratory confirmation of Diphtheria.
  • Subjects who received therapy with the intended DAT

Exclusion criteria

Exclusion Criteria:

  • Receiving a different brand of Diphtheria Antitoxin (DAT)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Investigational Product

    Diphtheria Antitoxin (DAT) Administered intravenously. Dosage: * Mild diphtheria (nose, skin): 20,000 unit * Moderate diphtheria (tonsil - limited): 40,000 - 60,000 unit * Severe diphtheria (more than 1 tonsil, or to the pharyngeal wall, or more than 5 days of illness, or with bull neck): 80,000 - 120,000 unit

    Biological: Diphtheria Antitoxin

Interventions

  • BiologicalDiphtheria Antitoxin

    Dosage form: Solution for injection Dosage: 1. Perform sensitivity tests, and desensitization if necessary. 2. Give the entire treatment dose of antitoxin IV (or IM) in a single administration (except for series of injections needed for desensitization). 3. The recommended DAT treatment dosage ranges (pediatric and adult) are: * Pharyngeal or laryngeal disease of 2 days duration 20,000 - 40,000 unit * Nasopharyngeal disease 40,000 - 60,000 unit * Extensive disease of 3 or more days duration, or any patient with diffuse swelling of neck 80,000 - 100,000 unit * Skin lesions only (rare case where treatment is indicated) 20,000 - 40,000 unit

06

What researchers measure

Primary outcomes

  1. The occurrence of serum sickness after administration of Diphtheria Antitoxin (DAT)

    Percentage of serum sickness after administration of Diphtheria Antitoxin (DAT)

    Time frame: Within 10 days after injection

Secondary outcomes

  1. The occurrence of local and systemic reactions after administration of Diphtheria Antitoxin (DAT)

    Percentage of local and systemic reaction after administration of Diphtheria Antitoxin (DAT)

    Time frame: Within 24 hours to 10 days after injection

  2. The occurrence of positive reaction after a sensitivity test (skin test) of Diphtheria Antitoxin (DAT)

    Percentage of positive reaction after sensitivity test (skin test) of Diphtheria Antitoxin (DAT)

    Time frame: Before injection of Diphtheria Antitoxin

  3. The occurrence of serious adverse event (SAE) after administration of Diphtheria Antitoxin (DAT)

    Percentage of serious adverse event (SAE) after administration of Diphtheria Antitoxin (DAT)

    Time frame: Within 10 days after injection

07

Study locations

1 site
  • RSUD Dr. Soetomo
    Surabaya, East Java 60286, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in May 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Sep 26, 2023
StartActual
Jan 31, 2023
Primary completionActual
May 13, 2023
CompletionActual
May 23, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06053853
Lead sponsor
PT Bio Farma
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Jan 31, 2023
Primary completion
May 13, 2023
Completion
May 23, 2023
Last update
Nov 18, 2023

Study contacts

Dominicus Husada, MD
principal investigator · Dr. Soetomo Hospital, Surabaya, Indonesia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion